Ryoko Tsukahara
Tokyo, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Secreted PLA2-III is a possible therapeutic target to treat neuropathic pain.
Journal: Biochemical and biophysical research communications
Published: May 27, 2021
Evaluation of the pharmacokinetics of 2-carba-cyclic phosphatidic acid by liquid chromatography-triple quadrupole mass spectrometry.
Journal: Prostaglandins & other lipid mediators
Published: October 17, 2019
The AGP-PPARγ axis promotes oxidative stress and diabetic endothelial cell dysfunction.
Journal: Molecular and cellular endocrinology
Published: October 13, 2017
LPA5 signaling is involved in multiple sclerosis-mediated neuropathic pain in the cuprizone mouse model.
Journal: Journal of pharmacological sciences
Published: September 13, 2017
Myelin-related gene silencing mediated by LPA1 - Rho/ROCK signaling is correlated to acetylation of NFκB in S16 Schwann cells.
Journal: Journal of pharmacological sciences
Published: April 15, 2016
Cyclic phosphatidic acid inhibits the secretion of vascular endothelial growth factor from diabetic human coronary artery endothelial cells through peroxisome proliferator-activated receptor gamma.
Journal: Molecular and cellular endocrinology
Published: February 26, 2015
Heart-type fatty-acid-binding protein (FABP3) is a lysophosphatidic acid-binding protein in human coronary artery endothelial cells.
Journal: FEBS open bio
Published: September 19, 2014
Cyclic phosphatidic acid relieves osteoarthritis symptoms.
Journal: Molecular pain
Published: January 31, 2014
Showing 1-11 of 11
Last Updated: 09/26/2026